The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Risk stratification–directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation
Abstract
We studied the impact of risk stratification–directed interventions for minimal residual disease (MRD) on relapse and disease-free survival (DFS) prospectively in 814 subjects with standard-risk acute leukemia receiving allotransplantation in first or second complete remission. A total of 709 subjects were MRD− after transplantation (Group A); 105 subjects were MRD+, 49 received low-dose IL-2 (Group B), and 56 received modified donor lymphocyte infusion (DLI) with or without low-dose IL-2 (Group C). Posttransplantation immune suppression for GVHD was also modified based on MRD state. The cumulative risk of relapse was significantly less and DFS was significantly better in subjects in Group C than in subjects in Group B (P = .001 and P = .002, respectively), but was not different from subjects in Group A (P = .269 and P = .688, respectively). Multivariate analyses confirmed that MRD state and modified DLI were significantly correlated with relapse (P = .000, odds ratio [OR] = 0.255 and P = .000, OR = 0.269) and DFS (P = .001, OR = 0.511 and P = .006, OR = 0.436, respectively). These data suggest that risk stratification–directed interventions with modified DLI in patients with standard-risk acute leukemia who are MRD+ after transplantation may improve transplantation outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International scoring system for evaluating prognosis in myelodysplastic syndromes
Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., et al. (1997) · Blood · doi:10.1182/blood.v89.6.2079 · Cited by 4,427
Slovak, M. L., Kopecky, K. J., Cassileth, P. A., Harrington, D. H., Theil, K. S., Mohamed, A., Paietta, E., Willman, C. L., Head, D. R., Rowe, J. M., et al. (2000) · Blood · doi:10.1182/blood.v96.13.4075 · Cited by 1,601
Collins, R. H., Shpilberg, O., Drobyski, W. R., Porter, D. L., Giralt, S., Champlin, R., Goodman, S. A., Wolff, S. N., Hu, W., Verfaillie, C., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.2.433 · Cited by 1,237
Bone-Marrow Transplantation: (Second of Two Parts)
Thomas, E. D., Storb, R., Clift, R. A., Fefer, A., Johnson, F. L., Neiman, P. E., Lerner, K. G., Glucksberg, H., & Buckner, C. D. (1975) · New England Journal of Medicine · doi:10.1056/nejm197504242921706 · Cited by 1,182
Logistic regression, survival analysis, and the Kaplan-Meier curve.
Efron, B. (1988) · Journal of the American Statistical Association · doi:10.1080/01621459.1988.10478612 · Cited by 1,065
Moorman, A. V., Harrison, C. J., Buck, G. A. N., Richards, S. M., Secker-Walker, L. M., Martineau, M., Vance, G. H., Cherry, A. M., Higgins, R. R., Fielding, A. K., et al. (2007) · Blood · doi:10.1182/blood-2006-10-051912 · Cited by 753
Regression modeling of competing risk using R: an in depth guide for clinicians
Scrucca, L., Santucci, A., & Aversa, F. (2010) · Bone Marrow Transplantation · doi:10.1038/bmt.2009.359 · Cited by 458
Huang, X.-J., Liu, D.-H., Liu, K.-Y., Xu, L.-P., Chen, H., Han, W., Chen, Y.-H., Wang, J.-Z., Gao, Z.-Y., Zhang, Y.-C., et al. (2006) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705445 · Cited by 432
Self-citationGrimwade, D., Jovanovic, J. V., Hills, R. K., Nugent, E. A., Patel, Y., Flora, R., Diverio, D., Jones, K., Aslett, H., Batson, E., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.1533 · Cited by 356
San Miguel, J. F., Vidriales, M. B., López-Berges, C., Dı́az-Mediavilla, J., Gutiérrez, N., Cañizo, C., Ramos, F., Calmuntia, M. J., Pérez, J. J., González, M., et al. (2001) · Blood · doi:10.1182/blood.v98.6.1746 · Cited by 335
Cited by
Chen, X., Xie, H., Wood, B. L., Walter, R. B., Pagel, J. M., Becker, P. S., Sandhu, V. K., Abkowitz, J. L., Appelbaum, F. R., & Estey, E. H. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3518 · Cited by 257
Metadata
- Authors
- Yan, C.-H., Liu, D.-H., Liu, K.-Y., Xu, L.-P., Liu, Y.-R., Chen, H., Han, W., Wang, Y., Qin, Y.-Z., & Huang, X.-J.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2012-04-05
- Volume
- 119
- Issue
- 14
- Pages
- 3256-3262
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2085749279
- Cited by
- 288
- References
- 18
- FWCI
- 14.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Risk stratification–directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. https://app.cochat.ai/papers/10.1182/blood-2011-09-380386
- The paper
- Yan, C.-H., Liu, D.-H., Liu, K.-Y., Xu, L.-P., Liu, Y.-R., Chen, H., Han, W., Wang, Y., Qin, Y.-Z., & Huang, X.-J. (2012). Risk stratification–directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood. https://doi.org/10.1182/blood-2011-09-380386
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.